SAB Biotherapeutics, Inc.
SABS · XNASCIK 1833214fmd_0PHBBVGTE8TJ5FK7XNKNN963G7Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 55 | 61 | 24 | 2 | 1 | 0 |
| Research and development | 28 | 57 | 36 | 17 | 30 | 34 |
| Total operating expenses | 35 | 74 | 53 | 40 | 44 | 49 |
| Operating income | 21 | (13) | (29) | (38) | (43) | (49) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | (4) | 10 | (4) | 9 | 62 |
| Income before taxes | 20 | (17) | (19) | (42) | – | 13 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 20 | (17) | (19) | (42) | – | 13 |
| Net income | 20 | (17) | (19) | (42) | (34) | 13 |
| Net income to common shareholders | 20 | – | (19) | (42) | (34) | 4 |